Sagimet Biosciences Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sagimet Biosciences Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 97% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-585.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 97% of Healthcare companies in United States.
Cash Cushion Ratio
+16%Cash, after subtracting all debt, equals 16% of its market value (net cash).
Higher than 59% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Sagimet Biosciences Inc. made a loss over the last year. Sagimet Biosciences Inc. owes $0.03 for every $1 it owns. Sagimet Biosciences Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSagimet Biosciences Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.75The share price is 2.75 times Sagimet Biosciences Inc.'s book value per share, higher than 53% of Healthcare companies in United States.
Market cap
$706 MThe total market value of all of Sagimet Biosciences Inc.'s shares at today's price (share price × number of shares), larger than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$256 MWhat Sagimet Biosciences Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.61Net worth divided by the number of shares. The share price of $9.95 is 2.8 times this, which is the P/B above.
Return on equity (ROE)
-24.4%Sagimet Biosciences Inc. lost 24.4% of its shareholders' money over the last year, higher than 64% of Healthcare companies in United States.
Owes vs Owns
0.03×Sagimet Biosciences Inc. owes $0.03 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Dividend yield
NoneSagimet Biosciences Inc. does not currently pay a dividend.
Profit growth
LossSagimet Biosciences Inc. made a loss in each of the last two years.
Cash vs debt
Net cashSagimet Biosciences Inc. held $113 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sagimet Biosciences Inc.: $706 M ÷ $256 M (30 Jun 2026) = 2.8.
What is Sagimet Biosciences Inc.'s return on equity?
Sagimet Biosciences Inc. lost 24.4% of its shareholders' money over the last year, higher than 64% of Healthcare companies in United States.
How much does Sagimet Biosciences Inc. owe compared with what it owns?
Sagimet Biosciences Inc. owes $0.03 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Does Sagimet Biosciences Inc. pay a dividend?
No. Sagimet Biosciences Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.